07:21:57 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-05-30 Bokslutskommuniké 2024
2024-02-29 Kvartalsrapport 2024-Q3
2023-12-04 Kvartalsrapport 2024-Q2
2023-10-04 Ordinarie utdelning INTEG B 0.00 SEK
2023-09-27 Årsstämma 2024
2023-08-31 Kvartalsrapport 2024-Q1
2023-06-08 Bokslutskommuniké 2023
2023-03-01 Kvartalsrapport 2023-Q3
2022-12-01 Kvartalsrapport 2023-Q2
2022-10-03 Ordinarie utdelning INTEG B 0.00 SEK
2022-09-28 Årsstämma 2023
2022-08-31 Kvartalsrapport 2023-Q1
2022-06-10 Bokslutskommuniké 2022
2022-03-02 Kvartalsrapport 2022-Q3
2021-12-02 Kvartalsrapport 2022-Q2
2021-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2021-09-02 Kvartalsrapport 2022-Q1
2021-05-31 Bokslutskommuniké 2021
2021-03-03 Kvartalsrapport 2021-Q3
2020-12-02 Kvartalsrapport 2021-Q2
2020-09-30 Årsstämma 2021
2020-09-09 Ordinarie utdelning INTEG B 0.00 SEK
2020-08-24 Kvartalsrapport 2021-Q1
2020-06-08 Bokslutskommuniké 2020
2020-04-20 Extra Bolagsstämma 2020
2020-03-02 Kvartalsrapport 2020-Q3
2019-12-02 Kvartalsrapport 2020-Q2
2019-09-30 Årsstämma 2020
2019-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2019-09-02 Kvartalsrapport 2020-Q1
2019-06-10 Bokslutskommuniké 2019
2019-03-04 Kvartalsrapport 2019-Q3
2018-12-17 Kvartalsrapport 2019-Q2
2018-09-25 Ordinarie utdelning INTEG B 0.00 SEK
2018-09-24 Årsstämma 2019
2018-09-24 Kvartalsrapport 2019-Q1
2018-06-25 Bokslutskommuniké 2018
2018-03-26 Kvartalsrapport 2018-Q3
2017-12-18 Kvartalsrapport 2018-Q2
2017-09-25 Årsstämma 2018
2017-09-25 Kvartalsrapport 2018-Q1
2017-06-30 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Integrum är verksamt inom medicinteknik. Idag utvecklar bolaget system för skelettförankrade proteser baserat på det framtagna OPRA-implantatsystemet, som senare vidaresäljs till sjukhus världen över. Implantatet sätts på patientens ben med hjälp utav titanskruvar och antas förbättra livet för en stor del patienter med amputation. Bolaget grundades 1998 och har sitt huvudkontor i Mölndal.
2022-07-04 10:04:02

Mölndal, Sweden, July 4, 2022 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company will consolidate its marketing organization to the US subsidiary. The department will be headed by the company's VP Global Marketing, who will oversee the company's marketing efforts in the US and globally.

Integrum's collected marketing efforts will be coordinated from the US site, thus streamlining the company's market outreach. The updated organization will be led by Ian Dawson, VP Global Marketing, who has previously managed Integrum's US marketing operations. He will report to Integrum's CEO Rickard Brånemark and Thomas Dugan, President of Integrum's US operations.

Ian Dawson has held senior global marketing positions for a number of leading medical device companies. His experience includes over 25 years of marketing of orthopaedic implant systems and market value creation with new disruptive technologies, including surgical robotics. He has previously held roles as Vice President Marketing for North America at Smith and Nephew Wound Management, Senior Vice President of Marketing for MAKO Surgical. In his most recent role, he led the US commercial marketing launch of the Zimmer Biomet orthopaedic robotic platform. 

"We are seeing a positive development in our outreach in the US market,  based on structured efforts made during the last year. Apart from focusing on market penetration in the US, the updated marketing organization will also coordinate our global outreach by leveraging on lessons learned from the world's largest medtech market," comments Rickard Brånemark, CEO of Integrum.